Direct answer. Smoking damages the heart and blood vessels. Public clinical guidance recommends quitting and avoiding secondhand smoke, including for people who already have cardiovascular disease. Support, medicines and an individual plan can be discussed with a clinician or stop-smoking service. A product claim or general recovery timeline does not provide personal treatment instructions. CDC cigarettes and cardiovascular disease, September 17, 2024.
- Occasional smoking is not a harmless cardiovascular exposure.
- Secondhand smoke matters for people who do not smoke.
- Quit support should account for heart disease, medicines and previous attempts.
- Nicotine replacement, prescribed medicines and vaping are different exposures.
- Tell the prescribing team when smoking stops, restarts or changes substantially.
- Do not dismiss new chest symptoms or severe distress as nicotine withdrawal.
Evidence summary
| Question | Source role | Conclusion and confidence |
|---|---|---|
| Is smoking merely associated with heart disease? | Public cardiovascular harm framework | Guidance identifies smoking as a cause of vascular harm; no individual event prediction supplied. |
| Does quitting remain relevant after a cardiac diagnosis? | NHLBI and CDC care context | Yes. Quitting is recommended alongside the actual cardiac plan. |
| Is vaping equivalent to either smoking or no exposure? | Different UK/US public frameworks | No. Complete substitution, continuing smoking and never using nicotine are different comparisons. |
| Does a public campaign clear every treatment trial? | Funding boundary | No. Original drug/device funding and methods need separate review. |
| Can changing smoking affect prescriptions? | Regulator monitoring notices | Yes, for selected medicines; ask the prescribing team rather than self-adjusting. |
Confidence is high in the need for condition-specific assessment and urgent attention to warning signs; recommendations are attributed clinical context, not independently certified treatment effects. The treatment section attributes clinical guidance; it does not certify the funding of every underlying intervention trial. Independent comparative outcome certainty and a supplement replacement regimen were not established by this focused review. A public institution or independent review cannot make a sponsored original trial financially independent.
Smoking, cardiovascular disease and secondhand exposure
Cardiovascular disease includes disorders of the heart and blood vessels. Smoking can contribute to atherosclerosis, where plaque develops in arteries, as well as other harmful vascular changes. The concern is not confined to the lungs or to someone with a high daily cigarette count. NHLBI also identifies occasional smoking as harmful. NHLBI smoking and heart/blood-vessel health, March 24, 2022.
Secondhand smoke comes from burning tobacco and smoke breathed out by someone who smokes. People can be exposed at home, at work or in other spaces. CDC identifies coronary and stroke harm in people who do not smoke. A person’s own smoking status therefore does not describe every relevant exposure. CDC secondhand smoke, May 15, 2024.
Smoking-related risk is not a diagnosis from one symptom. Symptoms can have other causes. Smoking history informs assessment; it does not explain every later symptom.
Vessel injury, clotting and nicotine dependence
NHLBI describes damage to vessel structure and function, inflammation, changes in heart rate and pressure, and impaired blood oxygen transport. These pathways help explain cardiovascular harm. They are different from a home test showing which pathway caused a particular event or how much risk an individual has now. NHLBI smoking risks, March 24, 2022.
Plaque buildup and clot formation are related but different processes. A narrowed vessel can affect blood supply, while a clot may cause a sudden blockage. CDC describes smoking-related damage to vessel lining and a greater tendency for blood to clot. This guide does not supply a numerical risk multiplier or infer one from a cigarette count. CDC cigarettes and cardiovascular disease, September 17, 2024.
Nicotine dependence helps explain cravings and repeated use. The current NHS withdrawal page describes restlessness, irritability, concentration problems, sleep difficulty and low mood after stopping. Dependence deserves practical support. A symptom list should not be used to label severe illness, a medicine reaction or a mental-health crisis as routine withdrawal. NHS Better Health current withdrawal discussion; exact revision date unclosed.
Quitting support, nicotine replacement and prescribed options
NHLBI recommends quitting even after coronary disease has been diagnosed. Quitting is part of wider care, alongside the medicines and procedures indicated for that condition. This article attributes the recommendation without supplying the dated page’s numerical benefit estimate or a guarantee that existing plaque or organ damage disappears. NHLBI quitting context, March 24, 2022; numerical benefits excluded.
Professional support can help establish a plan, discuss previous attempts and review treatment options. NHS England campaign guidance describes individual or group contact in person, by phone or video. Contact the actual service to check access and what it offers. England eligibility and free-service statements do not establish access worldwide. NHS Better Health current England support-service context.
Nicotine replacement therapy includes forms such as patches, gum, lozenges and sprays. The NHS describes their purpose as managing cravings without cigarette smoke. That is clinical context rather than an independently cleared ranking of brands, combinations or event outcomes. The pharmacist or clinician should explain suitability and the actual instructions. NHS Better Health current nicotine-replacement context; exact revision date unclosed.
The current NHS nicotine-free medicine page discusses varenicline, cytisine and bupropion. Availability, indications and suitability need local confirmation. This guide gives no dose, combination or recommendation to obtain a product independently; it does not adopt the campaign’s comparative-success multipliers. A plant-derived medicine is not automatically an unrestricted supplement. NHS Better Health current nicotine-free medicine context; exact revision date unclosed.
Triggers, complementary claims and herb interactions
Recognizing triggers can help planning. NHLBI suggests reviewing situations linked to smoking and what made earlier attempts difficult. A plan can address a break at work, a social setting or a familiar routine rather than relying only on a promise to resist. Chosen alternatives still need to fit cardiac activity restrictions. NHLBI quit planning, March 24, 2022.
NCCIH’s January 2021 page describes limited or inconsistent evidence for several complementary quitting approaches. It does not establish a reliably effective supplement replacement. Its current-looking website footer is not a 2026 clinical revision of that article, and its old cytisine-development status is not adopted here. NCCIH complementary quitting approaches, January 2021; commercial partnership disclosed.
A natural-product label does not remove interaction concerns. The more recent NCCIH St John’s wort page identifies important medicine interactions. Do not add an herb to manage withdrawal or mood without checking prescriptions. This source set does not provide an independently certified detox, antioxidant or herbal quitting regimen. NCCIH St John’s wort, May 2025; selected interactions, efficacy excluded.
Abstinence outcomes, vaping comparisons and trial independence
Track outcomes honestly. Not smoking, reduced cigarette use, cravings, carbon-monoxide measurements and cardiovascular events answer different questions. A lower exposure marker is not proof of zero risk or that heart disease has resolved. Keep the actual smoking history and treatment changes available for clinical review.
Vaping produces aerosol rather than cigarette smoke. The current NHS England campaign presents it as an option for adults who smoke and want to quit, while warning that it is not harmless and long-term effects remain uncertain. This is attributed advice, not a financially cleared brand comparison or numerical safety claim. NHS Better Health current vaping context; effect/clearance claims excluded.
CDC’s dated US framework distinguishes possible complete substitution for adults who smoke from youth, pregnancy or people who have never smoked. Continuing to smoke while vaping is a different comparison. The frameworks and regulatory statements are country-specific; this guide does not infer current authorization or complete long-term cardiac safety. CDC vaping framework, January 31, 2025; dated regulatory status excluded.
A public guideline or campaign may include manufacturer-funded medicine or device trials. Institutional funding does not clear those original financial chains. Under this site’s strict standard, supplier-funded or supplied-product outcomes are Tier 4/Grade D for independence. No comparative drug or vape efficacy verdict is independently certified here.
Chest symptoms, difficult withdrawal and mental-health emergencies
Concerning chest discomfort, spreading pain, breathlessness, sweating or nausea needs emergency attention; severe breathing difficulty or collapse also requires emergency help. Do not wait for a quit appointment or assume a new symptom is harmless because smoking has recently stopped. Use your local emergency service. NHLBI heart-attack symptoms, March24,2022.
Withdrawal symptoms vary. Ask for review if mood, sleep or concentration problems are difficult to manage, persistent or worsening. The NHS withdrawal source describes preparation and support, but it does not decide whether an individual needs assessment for another condition. No fixed symptom-duration reassurance is supplied. NHS Better Health current withdrawal discussion; exact revision date unclosed.
If life is at risk, someone has taken an overdose or you cannot keep yourself or another person safe, seek emergency help. Distress during a quit attempt deserves care rather than shame or pressure to continue without support. Local crisis services differ outside England. NHS urgent mental-health help, April 26, 2023; review overdue.
Smoke-related medicine processing and clozapine monitoring
Changing smoking can change how selected medicines are processed. The MHRA’s dated interaction notice explains smoke-related enzyme induction and the need to review medicines when smoking changes. This is not simply the amount of nicotine on a patch label. No dose change or old blanket hospital-exemption statement is adopted. MHRA October 2009 medicine/smoking notice; web publication December 2014.
The MHRA’s August 2020 clozapine notice identifies stopping smoking or switching to an e-cigarette as circumstances needing blood-level monitoring for toxicity. Starting or restarting smoking can also affect levels. Tell the mental-health prescriber; this monitoring does not replace the separate required blood tests for other clozapine risks. MHRA clozapine monitoring notice, August 26, 2020.
Bring prescriptions, nonprescription products, supplements and actual smoking or vaping habits to the review. Explain changes during a hospital admission as well as planned attempts at home. The treating team decides monitoring and any adjustment; do not independently stop a cardiac or psychiatric medicine to make quitting simpler.
Review a proposed quit treatment with the pharmacist or prescriber, including kidney disease, pregnancy, mental-health history, allergies and other medicines. A campaign listing several options does not establish that they can all be combined safely for every person. Current product information and the clinical plan govern the actual use.
Non-smokers, young people, pregnancy and shared smoke exposure
People who do not smoke should not start smoking or take up vaping as a heart-health strategy. CDC advises against vaping for youth and pregnancy. Someone already using nicotine should seek suitable cessation support rather than reading this as permission to adopt a new commercial product. CDC vaping framework, January 31, 2025; dated regulatory status excluded.
Pregnancy needs specialist support. The dated NHS pregnancy page asks people to consult a midwife, pharmacist or stop-smoking adviser about products. The page’s scheduled review is overdue; this guide supplies neither blanket drug/vape clearance nor a patch schedule. Include cardiac disease and the full medicine list in the maternity discussion. NHS pregnancy quitting page, January 10, 2023; review overdue.
Protect others from tobacco smoke in homes, cars and shared environments. CDC explains that exposure can occur even in multi-unit housing where someone does not smoke in their own home. Discuss practical smoke-free arrangements and building or workplace support. This guide does not supply a legal conclusion about a particular premises. CDC secondhand smoke, May 15, 2024.
Preparing support, access and returning after a setback
Prepare an account of cigarettes and other products, situations linked to use, previous attempts and what support was useful. Say whether heart symptoms or hospital treatment have changed. The current NHS preparation page discusses planning and professional support; it is not a self-diagnostic dependence score. NHS Better Health current quit-planning body; exact revision date unclosed.
Choose a support format you can access. NHS guidance includes pharmacy, primary care, telephone and other options. Consider work times, transport, language, privacy and costs. Digital reminders may be useful for organization but should not replace a review of symptoms, medicine interactions or adverse effects. NHS Better Health current support-format choices.
If smoking resumes, explain what happened and return to the plan with the service. NHLBI suggests learning from the situation rather than abandoning the attempt. Also tell relevant prescribers, because restarting can matter for medicines. A setback is information for care, not proof that support cannot be useful. NHLBI quit planning, March 24, 2022.
Exposure mechanisms versus human quit and cardiac outcomes
Laboratory and animal work can explain exposure pathways but cannot give a personal quit-product dose or a cardiovascular event estimate. Craving relief, measured abstinence, adverse effects and long-term cardiac outcomes are separate. Public reviews do not remove sponsorship of their underlying trials. This article uses clinical recommendations and warnings as attributed context; it does not convert sponsored outcomes into an independent efficacy ranking.
Funding and source roles
Who paid for the evidence?
Follow named sources to the funding and relationships disclosed in this article. Numbered article disclosures preserve notes where a source is not identified. A public or university name alone does not establish independence.
View 28 more funding disclosures
This graphic reorganizes the article's disclosures; it is not a new financial audit or independence classification. Highlighted notes show different funding relationships where available. Review funding is separate from underlying trial funding. Disclosure is not proof of falsehood, and no declared conflict is not proof of complete independence.
Tobacco, vape, nicotine-medicine and supplement companies have commercial interests that differ from the clinical goal of avoiding smoke exposure. Public institutional appropriations and gift policies are traced separately from original product trials. The NCCIH page explicitly reports a commercial-development partnership; its dated product status and benefit claims are excluded. No supplier-funded outcome is adopted as an independent verdict.
The clinical subject has no single corporate owner; medicines, devices and supplements have separate commercial ownership and financial interests. Medicines, diagnostics, devices, procedures and marketed supplements create different revenue incentives. This describes financial interests rather than misconduct. Funding tier evaluates proximity to the subject; A–D credibility assesses transparency, accuracy incentives and remaining uncertainty. An unresolved link stays unresolved, and a provisional public-information label does not clear the trials behind it.
| Source | Funding / backers | Country / jurisdiction | Independence | Credibility / incentives / gaps |
|---|---|---|---|---|
| NHLBI smoking and heart/blood-vessel health, March 24, 2022 | NIH/HHS appropriations and gift route. Page/contributor/original-study finance unclosed. | United States; NHLBI, Bethesda, Maryland. Underlying studies have separate jurisdictions. | Tier 1 public education provisional; original treatment-trial independence unclassified. | C provisional — actual March 2022 body read. Public-care accuracy incentive; dated education. Numerical risk/benefit, fixed recovery timelines, home medicine doses and individual clearance excluded. Role: Smoking, secondhand exposure and existing cardiovascular risk. |
| NHLBI smoking risks, March 24, 2022 | NIH/HHS appropriations and gift route. Page/contributor/original-study finance unclosed. | United States; NHLBI, Bethesda, Maryland. Underlying studies have separate jurisdictions. | Tier 1 public education provisional; original treatment-trial independence unclassified. | C provisional — actual March 2022 body read. Public-care accuracy incentive; dated education. Numerical risk/benefit, fixed recovery timelines, home medicine doses and individual clearance excluded. Role: Selected blood-vessel, inflammation and clotting mechanisms. |
| NHLBI quitting context, March 24, 2022; numerical benefits excluded | NIH/HHS appropriations and gift route. Page/contributor/original-study finance unclosed. | United States; NHLBI, Bethesda, Maryland. Underlying studies have separate jurisdictions. | Tier 1 public education provisional; original treatment-trial independence unclassified. | C provisional — actual March 2022 body read. Public-care accuracy incentive; dated education. Numerical risk/benefit, fixed recovery timelines, home medicine doses and individual clearance excluded. Role: Attributed quitting recommendation, numerical estimates excluded. |
| NHLBI quit planning, March 24, 2022 | NIH/HHS appropriations and gift route. Page/contributor/original-study finance unclosed. | United States; NHLBI, Bethesda, Maryland. Underlying studies have separate jurisdictions. | Tier 1 public education provisional; original treatment-trial independence unclassified. | C provisional — actual March 2022 body read. Public-care accuracy incentive; dated education. Numerical risk/benefit, fixed recovery timelines, home medicine doses and individual clearance excluded. Role: Triggers, preparation, support and restarting a quit attempt. |
| CDC cigarettes and cardiovascular disease, September 17, 2024 | CDC FY2026 budget authority/PPHF; separate gift rules. Actual donors, page and original-study finance unclosed. | United States; CDC Atlanta, Georgia; NCCDPHP/Office on Smoking and Health. Study jurisdictions separate. | Tier 1 public education provisional; original efficacy financial chain unclassified. | B provisional — actual dated selected body read. Public-health accuracy and policy incentives; simplification and original-study gaps. No numerical event effect or current complete licensing census. Role: Selected cardiovascular harm and quitting framework. |
| CDC secondhand smoke, May 15, 2024 | CDC FY2026 budget authority/PPHF; separate gift rules. Actual donors, page and original-study finance unclosed. | United States; CDC Atlanta, Georgia; NCCDPHP/Office on Smoking and Health. Study jurisdictions separate. | Tier 1 public education provisional; original efficacy financial chain unclassified. | B provisional — actual dated selected body read. Public-health accuracy and policy incentives; simplification and original-study gaps. No numerical event effect or current complete licensing census. Role: Secondhand smoke and smoke-free environments. |
| CDC vaping framework, January 31, 2025; dated regulatory status excluded | CDC FY2026 budget authority/PPHF; separate gift rules. Actual donors, page and original-study finance unclosed. | United States; CDC Atlanta, Georgia; NCCDPHP/Office on Smoking and Health. Study jurisdictions separate. | Tier 1 public education provisional; original efficacy financial chain unclassified. | B provisional — actual dated selected body read. Public-health accuracy and policy incentives; simplification and original-study gaps. No numerical event effect or current complete licensing census. Role: Dated US vaping framework, uncertainty and youth precautions. |
| NHS Better Health current quit-planning body; exact revision date unclosed | National NHS DHSC-funded editorial policy; institutional accounts are separate. Campaign/page allocation, suppliers and contributors unclosed. | United Kingdom; national England NHS/Better Health education. Local service access and medicine rules differ. | Tier 1 public education provisional; original medicine/vape trial finance unclassified. | C provisional — actual current campaign body read; no exact clinical revision date found. Public quitting-policy incentive; campaign allocation, authors and source trials unclosed. Effect multipliers, broad safety reassurance, brands and personal combinations excluded. Role: Current preparation/support categories, no self-dependence score. |
| NHS Better Health current nicotine-replacement context; exact revision date unclosed | National NHS DHSC-funded editorial policy; institutional accounts are separate. Campaign/page allocation, suppliers and contributors unclosed. | United Kingdom; national England NHS/Better Health education. Local service access and medicine rules differ. | Tier 1 public education provisional; original medicine/vape trial finance unclassified. | C provisional — actual current campaign body read; no exact clinical revision date found. Public quitting-policy incentive; campaign allocation, authors and source trials unclosed. Effect multipliers, broad safety reassurance, brands and personal combinations excluded. Role: Selected current nicotine-replacement forms and purpose. |
| NHS Better Health current nicotine-free medicine context; exact revision date unclosed | National NHS DHSC-funded editorial policy; institutional accounts are separate. Campaign/page allocation, suppliers and contributors unclosed. | United Kingdom; national England NHS/Better Health education. Local service access and medicine rules differ. | Tier 1 public education provisional; original medicine/vape trial finance unclassified. | C provisional — actual current campaign body read; no exact clinical revision date found. Public quitting-policy incentive; campaign allocation, authors and source trials unclosed. Effect multipliers, broad safety reassurance, brands and personal combinations excluded. Role: Selected current nicotine-free medicine categories, no prescribing menu. |
| NHS Better Health current England support-service context | National NHS DHSC-funded editorial policy; institutional accounts are separate. Campaign/page allocation, suppliers and contributors unclosed. | United Kingdom; national England NHS/Better Health education. Local service access and medicine rules differ. | Tier 1 public education provisional; original medicine/vape trial finance unclassified. | C provisional — actual current campaign body read; no exact clinical revision date found. Public quitting-policy incentive; campaign allocation, authors and source trials unclosed. Effect multipliers, broad safety reassurance, brands and personal combinations excluded. Role: England service contact and professional-support example. |
| NHS Better Health current support-format choices | National NHS DHSC-funded editorial policy; institutional accounts are separate. Campaign/page allocation, suppliers and contributors unclosed. | United Kingdom; national England NHS/Better Health education. Local service access and medicine rules differ. | Tier 1 public education provisional; original medicine/vape trial finance unclassified. | C provisional — actual current campaign body read; no exact clinical revision date found. Public quitting-policy incentive; campaign allocation, authors and source trials unclosed. Effect multipliers, broad safety reassurance, brands and personal combinations excluded. Role: Practical in-person, telephone, pharmacy and digital choices. |
| NHS Better Health current withdrawal discussion; exact revision date unclosed | National NHS DHSC-funded editorial policy; institutional accounts are separate. Campaign/page allocation, suppliers and contributors unclosed. | United Kingdom; national England NHS/Better Health education. Local service access and medicine rules differ. | Tier 1 public education provisional; original medicine/vape trial finance unclassified. | C provisional — actual current campaign body read; no exact clinical revision date found. Public quitting-policy incentive; campaign allocation, authors and source trials unclosed. Effect multipliers, broad safety reassurance, brands and personal combinations excluded. Role: Selected withdrawal symptoms and planning, no fixed timeline. |
| NHS Better Health current vaping context; effect/clearance claims excluded | National NHS DHSC-funded editorial policy; institutional accounts are separate. Campaign/page allocation, suppliers and contributors unclosed. | United Kingdom; national England NHS/Better Health education. Local service access and medicine rules differ. | Tier 1 public education provisional; original medicine/vape trial finance unclassified. | C provisional — actual current campaign body read; no exact clinical revision date found. Public quitting-policy incentive; campaign allocation, authors and source trials unclosed. Effect multipliers, broad safety reassurance, brands and personal combinations excluded. Role: Attributed England adult quitting context, harms/long-term gaps. |
| NHS pregnancy quitting page, January 10, 2023; review overdue | National NHS DHSC-funded editorial policy; institutional accounts are separate. Campaign/page allocation, suppliers and contributors unclosed. | United Kingdom; national England NHS/Better Health education. Local service access and medicine rules differ. | Tier 1 public education provisional; original medicine/vape trial finance unclassified. | C provisional — actual January 2023 body read; January 2026 scheduled review overdue. Selected specialist support only; no blanket pregnancy clearance, patch duration or current licensing claim. Role: Dated pregnancy specialist-support context only. |
| NHS urgent mental-health help, April 26, 2023; review overdue | National NHS DHSC-funded editorial policy; institutional accounts are separate. Campaign/page allocation, suppliers and contributors unclosed. | United Kingdom; national England NHS/Better Health education. Local service access and medicine rules differ. | Tier 1 public education provisional; original medicine/vape trial finance unclassified. | C provisional — actual April 2023 urgent/emergency body read; April 2026 scheduled review overdue. Local service numbers differ abroad. Selected safety context only; no diagnostic screen or efficacy claim. Role: Selected crisis/emergency safety, local services differ. |
| MHRA October 2009 medicine/smoking notice; web publication December 2014 | MHRA actual regulatory/customer-fee and DHSC-grant accounts. Notice contributors, case reports and supporting study finance unclosed. | United Kingdom; MHRA, Canary Wharf, London. Supporting case/supplier jurisdictions unresolved. | Tier 2 public-and-fee-funded regulator safety context, provisional; trial independence unclassified. | C provisional — actual dated original read. Public safety incentive and regulatory fees separate from trial sponsorship. Selected medicine-review/monitoring purpose only; old hospital no-adjustment statement, numeric thresholds, timings and personal dose changes excluded. Role: Dated smoke/medicine metabolism and review principle. |
| MHRA clozapine monitoring notice, August 26, 2020 | MHRA actual regulatory/customer-fee and DHSC-grant accounts. Notice contributors, case reports and supporting study finance unclosed. | United Kingdom; MHRA, Canary Wharf, London. Supporting case/supplier jurisdictions unresolved. | Tier 2 public-and-fee-funded regulator safety context, provisional; trial independence unclassified. | C provisional — actual dated original read. Public safety incentive and regulatory fees separate from trial sponsorship. Selected medicine-review/monitoring purpose only; old hospital no-adjustment statement, numeric thresholds, timings and personal dose changes excluded. Role: Selected monitoring when smoking changes, no dose algorithm. |
| NCCIH complementary quitting approaches, January 2021; commercial partnership disclosed | NCCIH historical appropriations and gift route. Original explicitly describes a commercial cytisine-development partnership; company/contract/page allocation and full reviewer/trial chains unclosed. | United States; NCCIH Bethesda, Maryland; named 2021 reviewer David Shurtleff. Complete partner/supplier jurisdictions unresolved. | Tier 3 public research/education with stated relevant commercial-development relationship; original product efficacy unclassified. | C provisional — actual January 2021 body/credit read. Public research and development interests; dated review with incomplete original trials. Selected uncertainty/interaction context only. Cytisine status, pooled benefits and blanket safety excluded. Role: Dated supplement/alternative uncertainty and commercial-development disclosure. |
| NCCIH St John’s wort, May 2025; selected interactions, efficacy excluded | NCCIH/NIH/HHS historical public appropriations and separate conditional/unconditional Gift Fund. Current receipts, reviewer outside ties and original supplement-trial chains unclosed. | United States; NCCIH/NIH Bethesda, Maryland. Donor, supplier and underlying-study jurisdictions unclosed. | Tier 1 public education route, provisional; contributor/trial independence unclassified. | C provisional — actual May 2025 body read selectively. Public safety incentive; complete contributors and herb/supplier study finance unclosed. Cardiovascular/serotonergic cautions only; efficacy review, safe-use duration and outcome comparisons excluded. Role: Selected current herb/medicine interaction warning. |
| Actual NCCIH appropriations history through FY2024; not a FY2026 total | Actual appropriation history ends FY2024; not current FY2026 spending or page allocation. | United States; NCCIH/NIH Bethesda, Maryland. Donor, supplier and underlying-study jurisdictions unclosed. | Tier 3 institutional financial self-report. | B provisional — actual appropriation/gift original read, with period limits. Public accountability and resource incentives; full named receipts and allocations unclosed. Finance only. Role: Historical public finance only, no inferred FY2026 total. |
| Actual NCCIH separate Gift Fund, conditional research gifts and Bethesda contact | Actual separate Gift Fund accepts donations/bequests, unconditional support or designated research gifts. Current named donor receipts, outside commercial contributors and page allocation unclosed. | United States; NCCIH/NIH Bethesda, Maryland. Donor, supplier and underlying-study jurisdictions unclosed. | Tier 3 institutional financial self-report. | B provisional — actual appropriation/gift original read, with period limits. Public accountability and resource incentives; full named receipts and allocations unclosed. Finance only. Role: Actual separate gift route, not page-specific donor attribution. |
| MHRA annual report and accounts 2025–26, actual financial/contact passages | Actual 2025–26 statutory accounts printed pp76–77 report £175.6m trading income from statutory industry regulatory fees and nonstatutory customer goods/services, plus £82.7m DHSC grant-in-aid recorded as taxpayers’ equity rather than operating income. Licence/vigilance/inspection/device fees, clinical-trial regulatory work, CPRD data-access licences and biological standards/services are described; p145 fee context read. Actual MHRA accounts. Complete named fee-payers, source-page allocation and supporting trial/author finances remain unclosed; regulator fees are not proof a particular company financed a notice. | United Kingdom; actual report printed p4 gives 10 South Colonnade, Canary Wharf, London, England. Full fee-payer jurisdictions unresolved. | Tier 3 statutory institutional self-report | B provisional — actual original read; statutory public accountability and safety-surveillance incentives, with industry fee reliance and incomplete financial chains disclosed. Institutional finance/contact only; not independent medicine efficacy evidence. Role: Actual regulator fee/public finance, not manufacturer trial clearance. |
| NHLBI heart-attack symptoms, March24,2022 | US federal appropriations; separate Gift Fund accepts donations and bequests, including support for public health information. Budget route; Gift authority. Actual donors, page allocation and underlying trial finances unresolved. | United States; NIH/NHLBI, Bethesda, Maryland; federal jurisdiction. | Tier 1 public education provisionally; donation route and page-specific chain unresolved. | C provisional — actual2022/2024 original body read selectively. Public educational accuracy incentive; dated generalizations and full source/underlying-trial financial gaps. Relative sex/race outcome claims, surgical-menopause simplification, blanket HRT harm, fixed risk tools/ages, symptom-severity reassurance and dose instructions excluded. Selected attributed warning signs, diagnostic purpose and care questions only. Role: Emergency cardiac symptom recognition. |
| NHS England actual audited2025–26 accounts | National NHS England: actual2025–26 audited accounts documents DHSC grant-in-aid as principal finance plus service, education/research and other consolidated income. content policy rejects advertising/corporate sponsorship. Exact page budget, contributor and underlying-trial financial chain unresolved; provider trusts have separate finances. | United Kingdom; national England patient information, institutional contact Leeds; local services and driving rules vary. | Tier 3 institutional financial self-report. | B provisional for actual statutory financial channels; no page/trial allocation or complete donor chain. |
| NHLBI budget | US federal appropriations; separate Gift Fund accepts donations and bequests, including support for public health information. Budget route; Gift authority. Actual donors, page allocation and underlying trial finances unresolved. | United States; NIH/NHLBI, Bethesda, Maryland; federal jurisdiction. | Tier 3 institutional financial self-disclosure. | B provisional. Direct public financial policy, with legal accountability; actual gift donors and allocations not audited. Financial provenance only. |
| NHLBI Gift Fund | US federal appropriations; separate Gift Fund accepts donations and bequests, including support for public health information. Budget route; Gift authority. Actual donors, page allocation and underlying trial finances unresolved. | United States; NIH/NHLBI, Bethesda, Maryland; federal jurisdiction. | Tier 3 institutional financial self-disclosure. | B provisional. Direct public financial policy, with legal accountability; actual gift donors and allocations not audited. Financial provenance only. |
| NHS national website funding policy | DHSC funds the national NHS website; its policy states no advertising or corporate sponsorship. Named authors, page-level budget and full underlying trial conflicts unresolved. | United Kingdom; England national public-information service. Other jurisdictions have different services. | Tier 3 editorial and financial self-disclosure. | B provisional. Explicit funding policy; actual individual declarations and implementation not audited. Financial provenance only. |
| CDC original FY2026 operating plan | Actual four-page FY2026 final operating plan distinguishes budget authority and Prevention and Public Health Fund support, including tobacco programme lines. No page-specific amount inferred. | United States; CDC Atlanta, Georgia, federal public-health jurisdiction. Archived surveillance handbook has international partner links; complete partner and backer financial chains not cleared. | Tier 3 institutional finance, policy or contact self-disclosure. | B provisional for actual selected institutional financial/policy passages. Statutory/public-policy incentives; self-report and allocation gaps remain. Finance only; no underlying trial clearance. Role: Financial provenance only. |
| CDC dated2016 gift authority,2022 editorial review | Actual 24-page gift policy permits conditional/unconditional, Foundation and in-kind gifts with review; printed p8 excludes tobacco corporations and related foundations. Actual donors, implementation and page allocation unclosed. | United States; CDC Atlanta, Georgia, federal public-health jurisdiction. Archived surveillance handbook has international partner links; complete partner and backer financial chains not cleared. | Tier 3 institutional finance, policy or contact self-disclosure. | B provisional for actual selected institutional financial/policy passages. Statutory/public-policy incentives; self-report and allocation gaps remain. Finance only; no underlying trial clearance. Role: Financial provenance only. |
| CDC actual Atlanta contact and public-site provenance | CDC/HHS federal budget authority and public transfers in FY2026 operating plan. Separate gift authority permits donations, bequests, in-kind support and CDC Foundation transfers with conflict review. These permitted routes do not prove a private gift financed this page. Named donors, page allocation and author/original-study finances unresolved. | United States; CDC Atlanta, Georgia, federal public-health jurisdiction. Archived surveillance handbook has international partner links; complete partner and backer financial chains not cleared. | Tier 3 institutional finance, policy or contact self-disclosure. | B provisional for documented finance routes and location. Gift policy is dated2016 with2022 editorial review; actual donors, implementation, page allocations and individual independence not audited. Financial provenance only. |
Frequently asked questions
Is occasional smoking harmless for the heart? No. Public guidance identifies harm even at low exposure.
Does quitting matter after a heart attack? Yes. It remains part of care alongside the prescribed cardiac plan.
Are nicotine patches the same as cigarettes? No. Replacement treatment and inhaled tobacco smoke are different exposures; suitability still needs review.
Is vaping risk-free? No. Source-specific adult quitting advice does not establish complete long-term safety.
Should I tell my prescriber when I stop or restart smoking? Yes, particularly with medicines affected by smoking, such as clozapine.
Can an herbal detox replace quit support? No independently established replacement was identified here.
Sources and funding notes
- NHLBI smoking and heart/blood-vessel health, March 24, 2022 — Smoking, secondhand exposure and existing cardiovascular risk.
- NHLBI smoking risks, March 24, 2022 — Selected blood-vessel, inflammation and clotting mechanisms.
- NHLBI quitting context, March 24, 2022; numerical benefits excluded — Attributed quitting recommendation, numerical estimates excluded.
- NHLBI quit planning, March 24, 2022 — Triggers, preparation, support and restarting a quit attempt.
- CDC cigarettes and cardiovascular disease, September 17, 2024 — Selected cardiovascular harm and quitting framework.
- CDC secondhand smoke, May 15, 2024 — Secondhand smoke and smoke-free environments.
- CDC vaping framework, January 31, 2025; dated regulatory status excluded — Dated US vaping framework, uncertainty and youth precautions.
- NHS Better Health current quit-planning body; exact revision date unclosed — Current preparation/support categories, no self-dependence score.
- NHS Better Health current nicotine-replacement context; exact revision date unclosed — Selected current nicotine-replacement forms and purpose.
- NHS Better Health current nicotine-free medicine context; exact revision date unclosed — Selected current nicotine-free medicine categories, no prescribing menu.
- NHS Better Health current England support-service context — England service contact and professional-support example.
- NHS Better Health current support-format choices — Practical in-person, telephone, pharmacy and digital choices.
- NHS Better Health current withdrawal discussion; exact revision date unclosed — Selected withdrawal symptoms and planning, no fixed timeline.
- NHS Better Health current vaping context; effect/clearance claims excluded — Attributed England adult quitting context, harms/long-term gaps.
- NHS pregnancy quitting page, January 10, 2023; review overdue — Dated pregnancy specialist-support context only.
- NHS urgent mental-health help, April 26, 2023; review overdue — Selected crisis/emergency safety, local services differ.
- MHRA October 2009 medicine/smoking notice; web publication December 2014 — Dated smoke/medicine metabolism and review principle.
- MHRA clozapine monitoring notice, August 26, 2020 — Selected monitoring when smoking changes, no dose algorithm.
- NCCIH complementary quitting approaches, January 2021; commercial partnership disclosed — Dated supplement/alternative uncertainty and commercial-development disclosure.
- NCCIH St John’s wort, May 2025; selected interactions, efficacy excluded — Selected current herb/medicine interaction warning.
- Actual NCCIH appropriations history through FY2024; not a FY2026 total — Historical public finance only, no inferred FY2026 total.
- Actual NCCIH separate Gift Fund, conditional research gifts and Bethesda contact — Actual separate gift route, not page-specific donor attribution.
- MHRA annual report and accounts 2025–26, actual financial/contact passages — Actual regulator fee/public finance, not manufacturer trial clearance.
- NHLBI heart-attack symptoms, March24,2022 — Emergency cardiac symptom recognition.
- NHS England actual audited2025–26 accounts — National institutional finance, not campaign or provider allocation.
- NHLBI budget — Financial provenance only.
- NHLBI Gift Fund — Financial provenance only.
- NHS national website funding policy — Financial provenance only.
- CDC original FY2026 operating plan — Financial provenance only.
- CDC dated2016 gift authority,2022 editorial review — Financial provenance only.
- CDC actual Atlanta contact and public-site provenance — Financial provenance only.
The selected clinical originals and institutional financial sources were opened, with access-limited author reports and corrections identified explicitly. Actual March2022 NHLBI smoking definition/risks/benefits/planning and September2024 CDC cardiovascular, May2024 secondhand and January2025 vaping bodies read. Numerical event effects, fixed recovery timelines and historical complete regulatory claims excluded. Actual current2026 NHS Better Health preparation, NRT, nicotine-free medicine, support-service/options, withdrawal and vaping bodies read; individual clinical revision dates absent and campaign benefit multipliers, brand hierarchy, unbounded combinations, pregnancy/vape assurances and rarity statements excluded. Actual January2023 pregnancy and April2023 urgent mental-health bodies read; scheduled2026 reviews overdue. Actual October2009 interaction notice(web2014) and August2020 clozapine warning read; old hospital no-adjustment statement excluded, selected medicine-review/monitoring purpose only. Actual January2021 NCCIH complementary body/credit and stated commercial cytisine-development partnership read; old status and original efficacy not adopted, full company/contract and trial chains unclosed. Actual May2025 StJohn interaction body already read. Actual four-page CDC FY2026 final operating-plan tobacco budget-authority/PPHF rows and 24-page gift-policy selected donation/conflict/tobacco-exclusion passages reopened. Actual NCCIH historical appropriation and separate gift bodies reopened; noFY2026 total inferred. MHRA2025–26 actual accounts previously read, public/industry-fee roles kept separate. No personal nicotine/medicine/combination plan. Guidance, classification, emergency education and independent efficacy are distinct source roles. A full systematic review, complete society donor audit and author-by-author clearance of original treatment trials were not completed.
Last reviewed: October 4, 2026. Educational information, not a diagnosis or personal treatment plan. Use your local emergency service for an emergency.
Have a question — or want us to cover something?
Ask about anything on this page, or request the next deep dive: an ingredient, a supplement, or a health concern. We use published research, evidence syntheses, and regulatory guidance, with clear source links.
One daily research roundup
Get the topics, key findings and links from our new articles in one email. At most one digest a day, only when there is something new.